Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report

Emerging targeted therapies in advanced bladder cancer

(2017) Yong Hyu Goh et al.   Translational Cancer Research

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2

(2015) Stéphane Oudard et al.   EUROPEAN JOURNAL OF CANCER

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer

(2015) Yeon Hee Park et al.   Oncotarget

HER2in solid tumors: more than 10 years under the microscope; where are we now?

(2014) Vittoria Martin et al.   Future Oncology

Somatic mutations of the HER2 in metastatic breast cancer

(2014) Yi Fang et al.   TUMOR BIOLOGY

Bladder Cancer: Current Management and Opportunities for a Personalized Approach

(2010) Matthew D. Galsky et al.   MOUNT SINAI JOURNAL OF MEDICINE

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

(2009) M. Lae et al.   ANNALS OF ONCOLOGY

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

(2009) Christian Wülfing et al.   CANCER